Telix Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Key Metrics
PE ratio
337.33
PB ratio
5.64
Dividend yield
-
Beta
1.10
Market cap
$3.39B
Enterprise value
$3.64B
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://telixpharma.com |
| Mailing address | 55 Flemington Road Level 4 North Melbourne VIC 3051 Australia |
| Phone / Fax | 61 3 9093 3855 / |
Dividends
More: Telix Pharmaceuticals Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Telix Pharmaceuticals paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.TLX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Telix Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D | Co-Founder, MD, Group CEO & Executive Director | 50 | |
| Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer | 60 | |
| Mr. Darren Patti Pharm.D. | Group Chief Operating Officer | 52 | |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor | 60 | |
| Dr. David N. Cade M.B.A., M.D., MBBS | Group Chief Medical Officer | 55 | |
| Mr. Richard Valeix M.B.A. | Chief Executive Officer of Telix Therapeutics | 49 | |
| Dr. Paul Schaffer | SVP of Research & Development | ||
| Mr. Craig Ulrick | Chief Information Officer | ||
| Ms. Kyahn Williamson B.A. | Senior Vice President of Corporate Communications & Investor Relations | ||
| Ms. Lena Moran-Adams L.L.B. | Group General Counsel |
Profitability and management effectiveness
Profit margin
1.63%
Operating margin
-0.30%
Return on assets
2.08%
Return on equity
3.14%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Telix Pharmaceuticals is 3.39B and its enterprise value is 3.64B. The enterprise value to revenue ratio of TLX is 5.47. The enterprise value to EBITDA ratio of TLX is 99.87.
The TLX's stocks Beta value is 1.10 making it 10% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Telix Pharmaceuticals (TLX)
Telix Pharmaceuticals (ASX:TLX) Frequently Asked Questions
1. What is Telix Pharmaceuticals's Stock Symbol?
Telix Pharmaceuticals trades on ASX under the ticker symbol "TLX".
2. What is Telix Pharmaceuticals's stock price today?
One share of TLX stock can currently be purchased for approximately $10.12.
3. How can I contact Telix Pharmaceuticals?
Telix Pharmaceuticals's mailing address is 55 Flemington Road Level 4 North Melbourne VIC 3051 Australia. The company can be reached via phone at 61 3 9093 3855.
4. What is Telix Pharmaceuticals's official website?
The official website of Telix Pharmaceuticals is https://telixpharma.com.